• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by China SXT Pharmaceuticals Inc.

    3/28/25 7:21:13 AM ET
    $SXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SXTC alert in real time by email

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    Form 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
    THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of March 2025

     

    Commission File Number: 001-38773

     

    CHINA SXT PHARMACEUTICALS, INC.

    (Translation of registrant’s name into English)

     

    178 Taidong Rd North, Taizhou

    Jiangsu, China 

    (Address of principal executive office)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

     

    Form 20-F ☒     Form 40-F ☐

     

     

     

     

    Explanatory Note

     

    China SXT Pharmaceuticals, Inc. (the “Company”) is furnishing this Form 6-K to provide its financial results for the six months ended September 30, 2024.

     

    The Company hereby furnishes the following documents as the exhibits to this report: “Unaudited Condensed Consolidated Financial Statements for the six months ended September 30, 2024 and 2023” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations”.

     

    1

     

    Exhibits

     

    Exhibit No.   Description
    99.1   Management’s Discussion and Analysis of Financial Condition and Results of Operations
    99.2   Unaudited Condensed Consolidated Financial Statements for the six months ended September 30, 2024 and 2023
    101.INS   Inline XBRL Instance Document.
    101.SCH   Inline XBRL Taxonomy Extension Schema Document.
    101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document.
    101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document.
    101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document.
    101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document.
    104   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

     

    2

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

    Dated: March 28, 2025

      

      China SXT Pharmaceuticals, Inc.
         
      By: /s/ Feng Zhou
      Name:  Feng Zhou
      Title: Co-Chief Executive Officer

     

      By: /s/ Simon Lim Sze Beng
      Name:  Simon Lim Sze Beng
      Title: Co-Chief Executive Officer

     

     

    3

     

    Get the next $SXTC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SXTC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SXTC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by China SXT Pharmaceuticals Inc.

      SC 13G/A - China SXT Pharmaceuticals, Inc. (0001723980) (Subject)

      10/25/24 12:19:29 PM ET
      $SXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by China SXT Pharmaceuticals Inc.

      SC 13G/A - China SXT Pharmaceuticals, Inc. (0001723980) (Subject)

      8/15/24 9:45:36 AM ET
      $SXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by China SXT Pharmaceuticals Inc. (Amendment)

      SC 13G/A - China SXT Pharmaceuticals, Inc. (0001723980) (Subject)

      5/31/24 10:36:52 AM ET
      $SXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SXTC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • China SXT Pharmaceuticals Has Regained Compliance with Nasdaq's Minimum Bid Price Deficiency

      TAIZHOU, China, March 17, 2025 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) (the "Company"),  a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces ("TCMPs"), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements ("TCMHS"), today announced that the Company received a written notification (the "Compliance Notice") from the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq") dated March 13, 2025, informing the Company that it has regained compliance with the Nasdaq Listing Ru

      3/17/25 8:30:00 AM ET
      $SXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • China SXT Pharmaceuticals, Inc. Announces Share Consolidation

      TAIZHOU, China, Feb. 21, 2025 (GLOBE NEWSWIRE) -- China SXT Pharmaceutics, Inc. (NASDAQ:SXTC) (the "Company" or "SXTC"),  a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces ("TCMPs"), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements ("TCMHS"), today announced that it will effect a share consolidation of its ordinary shares at a ratio of 1-for-8, effective on February 25, 2025 (the "Share Consolidation"). The Company's ordinary shares are expected to begin trading on a post-consolidation basis at the open of th

      2/21/25 12:35:28 PM ET
      $SXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • China SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price Deficiency

      Jiangsu, China, , Oct. 07, 2024 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. ("SXTC" or the "Company"), (NASDAQ:SXTC) announced today that on October 3, 2024, the Company received a notification letter from the Nasdaq Listing Qualifications Staff of The NASDAQ Stock Market LLC ("Nasdaq") notifying the Company that the minimum bid price per share for its ordinary shares has been below $1.00 for a period of 30 consecutive business days and the Company therefore no longer meets the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2). The notification received has no immediate effect on the listing of the Company's ordinary shares on Nasdaq. Under the Nasdaq List

      10/7/24 4:15:00 PM ET
      $SXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SXTC
    SEC Filings

    See more
    • SEC Form 424B5 filed by China SXT Pharmaceuticals Inc.

      424B5 - China SXT Pharmaceuticals, Inc. (0001723980) (Filer)

      5/19/25 8:00:24 AM ET
      $SXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by China SXT Pharmaceuticals Inc.

      6-K - China SXT Pharmaceuticals, Inc. (0001723980) (Filer)

      5/13/25 11:30:25 AM ET
      $SXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by China SXT Pharmaceuticals Inc.

      424B5 - China SXT Pharmaceuticals, Inc. (0001723980) (Filer)

      5/7/25 7:58:31 AM ET
      $SXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SXTC
    Leadership Updates

    Live Leadership Updates

    See more
    • Bon Natural Life Limited Appoints Wallace Lee as New Chief Financial Officer

      XIAN, China, April 25, 2023 (GLOBE NEWSWIRE) -- Bon Natural Life Limited (NASDAQ:BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, is pleased to announce the appointment of Mr. Wallace Lee as Chief Financial Officer (CFO), effective April 17, 2023. Mr. Lee succeeds Zhenchao Li, who stepped down from the role of CFO after a 4-year career with the Company, effective April 17, 2023. "We welcome Wallace Lee into BON's executive leadership team." Commented Richard Hu, "Wallace brings exceptional financial, strategic, and operational experience both from multiple industry sectors and experience as a public c

      4/25/23 8:30:00 AM ET
      $BON
      $SXTC
      $WSG
      Medicinal Chemicals and Botanical Products
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Services-Misc. Amusement & Recreation